Point72 (ANGO) reports 3.18M shares, 7.7% stake via Point72 Associates
Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has reported a beneficial ownership of 3,181,829 shares in AngioDynamics (ANGO), representing a 7.7% stake as of March 31, 2026. These shares are held through Point72 Associates, an investment fund managed by Point72 Asset Management, and involve shared voting and dispositive power. The filing clarifies the control relationships among the reporting entities, with Steven A. Cohen controlling both Point72 Asset Management and Point72 Capital Advisors Inc., but explicitly states that the reporting persons do not directly own these shares.
SmartPort Surgery Lawsuit Claims AngioDynamics Catheter Fractured Inside Woman’s Body
A Missouri woman has filed a product liability lawsuit against AngioDynamics Inc. and Navilyst Medical Inc., alleging that an AngioDynamics SmartPort catheter fractured inside her body, requiring surgical removal of a broken segment from major veins near her heart. The lawsuit claims the SmartPort was defectively designed and manufactured, and that the company concealed a higher failure rate compared to similar devices. This case joins numerous other AngioDynamics lawsuits consolidated in a multidistrict litigation, raising similar allegations against the manufacturers for alleged negligence, design defects, and failure to warn.
AngioDynamics Reports 'Durable Oncologic Control' in Study of NanoKnife for Intermediate-Risk Prostate Cancer
AngioDynamics reported durable oncologic control in a study of its NanoKnife system for intermediate-risk prostate cancer. The study showed a disease-free survival rate of 96% at two years, with minimal impact on urinary and sexual function. These positive results support the NanoKnife system's potential as a treatment option for prostate cancer patients.
AngioDynamics reports 24-month data from prostate cancer trial
AngioDynamics announced positive 24-month results from its PRESERVE pivotal trial for the NanoKnife System in treating intermediate-risk prostate cancer, showing 94.4% of patients completed the assessment with no new treatment failures. The company's stock shows significant upside potential according to analysts, despite being unprofitable, and the NanoKnife System continues to demonstrate its effectiveness through irreversible electroporation technology. Recent financial reports also indicate AngioDynamics surpassed Q3 2026 earnings and revenue expectations.
Angiodynamics Announces Two-Year Preserve Trial Data Demonstrating Durable Nanoknife Ire System Outcomes In Intermediate-Risk Prostate Cancer
Angiodynamics announced positive two-year data from its Preserve Trial, demonstrating durable outcomes for patients with intermediate-risk prostate cancer treated with the NanoKnife IRE System. This news, reported by Refinitiv, highlights the potential long-term efficacy of the NanoKnife system in this patient population. The article is very short, indicating a brief breaking news announcement.
Prostate cancer trial sees 0 new failures with NanoKnife at 2 years
AngioDynamics (NASDAQ: ANGO) announced positive two-year results from its PRESERVE pivotal trial for the NanoKnife System in treating intermediate-risk prostate cancer. The data showed sustained oncologic control and safety, with no new treatment failures between 12 and 24 months and 97% of patients having PSA levels below baseline. These findings reinforce the NanoKnife System as a durable and effective focal therapy option.
AngioDynamics introduces Soft Vu Angiographic Catheters with over 50 tip shapes
AngioDynamics has launched its new Soft Vu Angiographic Catheters, providing medical professionals with over 50 tip shapes to address diverse clinical needs and anatomical challenges. This introduction aims to enhance procedural flexibility and is a direct result of ongoing physician-driven innovation, incorporating feedback gathered from events like the SIR conference. The company emphasizes its commitment to integrating medical professional insights into product development.
136,333 Shares in AngioDynamics, Inc. $ANGO Bought by D.A. Davidson & CO.
D.A. Davidson & CO. has acquired a new stake of 136,333 shares, valued at approximately $1.75 million, in AngioDynamics, Inc. during the fourth quarter. This acquisition represents about 0.33% of the company's total shares, with institutional investors collectively owning 89.43%. Despite a consensus "Moderate Buy" rating with an $18.67 target, analyst sentiment is mixed, including recent downgrades and a price target reduction by Canaccord Genuity, while Weiss Research reiterated a "sell" rating.
AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Up 18.7% in April
AngioDynamics, Inc. (NASDAQ:ANGO) saw an 18.7% increase in short interest during April, reaching 2,161,213 shares, which represents about 5.6% of its shares sold short. This implies a 3.3 days-to-cover ratio based on average daily trading volume. Despite beating recent quarterly estimates, the company remains unprofitable, though analysts maintain a "Moderate Buy" rating with an average price target of $18.67.
AngioDynamics Catheter Lawsuit Claims SmartPort Device Embedded in Jugular Vein, Caused Embolism
A product liability lawsuit has been filed against AngioDynamics Inc. and Navilyst Medical Inc., alleging that a SmartPort catheter became embedded in a Michigan woman's jugular vein, causing an embolism and other complications. The complaint claims that the device was defectively designed due to the inclusion of barium sulfate, which may degrade the catheter material over time and lead to microfractures and device failure. This lawsuit joins over 300 similar AngioDynamics cases centralized in a multidistrict litigation, with bellwether trials expected to begin after initial selections in June.
Discipline and Rules-Based Execution in ANGO Response
Quantitative Research Desk provides an analysis of Angiodynamics Inc. (NASDAQ: ANGO), noting weak near-term sentiment that could shift mid and long-term outlooks. The report highlights a mid-channel oscillation pattern and an exceptional 53.7:1 risk-reward short setup. It also outlines three distinct trading strategies generated by AI models for different risk profiles.
Weber Capital Management LLC ADV Invests $17.98 Million in AngioDynamics, Inc. $ANGO
Weber Capital Management LLC ADV has made a significant investment of $17.98 million in AngioDynamics, Inc. (NASDAQ:ANGO), acquiring over 1.4 million shares which now represent 17% of the fund's holdings and 3.40% of AngioDynamics. The medical instruments supplier, despite slightly beating quarterly earnings estimates, remains unprofitable with a negative net margin. Analyst ratings for AngioDynamics are mixed, ranging from "strong-buy" to "sell," with an average target price of $18.67.
FY2026 EPS Estimates for AngioDynamics Increased by Analyst
Zacks Research has increased its FY2026 EPS estimate for AngioDynamics (NASDAQ:ANGO) from ($0.26) to ($0.23), while maintaining a "Hold" rating on the stock. Despite a "Moderate Buy" consensus rating from analysts, with various "Strong Buy," "Buy," "Hold," and "Sell" assignments, the average target price is $18.67. AngioDynamics recently surpassed earnings expectations, reporting ($0.07) EPS against an estimated ($0.11), with revenues of $78.42 million.
Quant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lag
This article provides a quantitative snapshot of stock performance, highlighting J. Jill and AngioDynamics as strong buys. Conversely, INmune Bio and Terrestrial Energy are identified as lagging in the current market analysis. The report likely details the factors contributing to these classifications through quantitative metrics.
AngioDynamics, Inc. (NASDAQ:ANGO) Given Consensus Recommendation of "Moderate Buy" by Analysts
AngioDynamics, Inc. (NASDAQ:ANGO) has received a "Moderate Buy" consensus rating from six analysts, with an average 12-month price target of $18.67. Institutional investors, including Kotler Kevin and Weber Capital, have significantly increased their positions, with overall institutional ownership at 89.43%. The company recently reported Q4 EPS of ($0.07) and revenue of $78.42 million, exceeding analyst estimates.
AngioDynamics files patent lawsuit against Endovascular Engineering
AngioDynamics has filed a patent infringement lawsuit against Endovascular Engineering (E2) in federal court in Delaware. The lawsuit alleges that E2's Hēlo Thrombectomy System infringes on AngioDynamics' patents related to self-expanding funnel technology for thrombi and emboli removal. AngioDynamics is seeking damages and equitable relief, emphasizing its commitment to protecting its intellectual property.
AngioDynamics Files Patent Suit to Protect Thrombectomy Technology
AngioDynamics has filed a patent infringement lawsuit against Endovascular Engineering, Inc. in the U.S. District Court for the District of Delaware. The suit alleges that E2’s Hēlo Thrombectomy System infringes upon AngioDynamics’ patents, specifically its proprietary self-expanding funnel technology. AngioDynamics is seeking damages and equitable relief to protect its intellectual property and competitive position in the vascular intervention market.
AngioDynamics files patent lawsuit against Endovascular Engineering
AngioDynamics has filed a patent infringement lawsuit against Endovascular Engineering (E2) over its Hēlo Thrombectomy System, alleging it uses AngioDynamics' proprietary self-expanding funnel technology. This comes as AngioDynamics recently reported better-than-expected Q3 2026 earnings and received a "Buy" rating from Freedom Broker, although Canaccord lowered its price target due to margin pressures. The medical device company seeks damages and equitable relief to protect its intellectual property.
[8-K] ANGIODYNAMICS INC Reports Material Event
AngioDynamics, Inc. (ANGO) has filed an 8-K report announcing a patent infringement lawsuit against Endovascular Engineering, Inc. (E2). The lawsuit alleges that E2's Hēlo Thrombectomy System infringes on AngioDynamics' patents relating to its self-expanding funnel technology, seeking damages and equitable relief. AngioDynamics stated its commitment to vigorously protecting its intellectual property rights to support innovation and patient care.
Physician insights guide AngioDynamics new innovation push at SIR 2026
AngioDynamics is intensifying its focus on physician-led innovation, drawing significant guidance from discussions held at SIR 2026 in Toronto. The company plans to integrate physician input into its R&D strategy, with specific project details expected in the coming months. This initiative builds on recent product launches and talent investments, underscoring AngioDynamics' commitment to advancing healthcare through practitioner collaboration.
AngioDynamics promotes Soft-Vu and Accu-Vu angiographic catheters at SIR event
AngioDynamics is showcasing its Soft-Vu and Accu-Vu angiographic catheters at the SIR event, inviting healthcare professionals to its booth to learn more about these products for patient care. The company recently launched the Mini Stick MAX Coaxial Microintroducer Kit and is also accepting applications for its 2026 summer internship program, highlighting its ongoing efforts in product development and workforce growth within the medical device sector.
ANGO SEC Filings - Angiodynamics 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Angiodynamics (ANGO) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It leverages AI-powered tools for summaries and sentiment analysis to help investors quickly interpret these regulatory documents. The article details recent 8-K filings concerning financial results and corporate governance, explaining how AngioDynamics categorizes its Med Tech and Med Device platforms.
AngioDynamics promotes solution portfolios at event booth
AngioDynamics is promoting its range of solutions at an event booth and online, encouraging attendees to learn more about the company's offerings. The company recently announced its 2026 summer internship program and unveiled the Mini Stick MAX Coaxial Microintroducer Kit. These initiatives highlight AngioDynamics' continued focus on expanding its medical device portfolio and workforce.
AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AngioDynamics (ANGO) has experienced a 5.8% decline in the past four weeks, but indicators suggest a potential trend reversal. The stock is technically in oversold territory based on its Relative Strength Index (RSI) of 9.16. Additionally, analysts have been raising earnings estimates for ANGO, and it holds a Zacks Rank #2 (Buy), further supporting the likelihood of a rebound.
Vortex Port Lawsuit Filed After Port Catheter Removed Due to Infection, Blood Clots
A lawsuit has been filed against AngioDynamics Inc. and Navilyst Medical Inc. by a Washington woman whose Vortex port catheter allegedly caused blood clots and infections, leading to its surgical removal and subsequent physical deformity. The plaintiff claims the device was defectively designed and manufactured, and that the companies failed to warn about known risks. This complaint joins over 300 similar lawsuits consolidated into a multidistrict litigation, with bellwether trials expected to influence potential settlements.
AngioDynamics (ANGO) Upgraded to Buy: Here's Why
AngioDynamics (ANGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting a positive shift in its earnings outlook. This upgrade is based on upward trends in earnings estimates by analysts, which is a strong indicator for potential stock price movements. The Zacks rating system emphasizes these revisions as a key factor in predicting near-term stock performance, positioning ANGO as a solid investment opportunity.
AngioDynamics projects average patient savings of 1,224 dollars with SmartPort Plus adoption
AngioDynamics has launched its SmartPort Plus device with Vortex technology, anticipating average patient savings of $1,224 compared to traditional port systems. The company aims to enhance efficiency, reduce costs, and allow healthcare professionals more time for patient care. This release continues AngioDynamics' commitment to advancing healthcare technology, following other recent product introductions and a 2026 summer internship program.
(ANGO) Movement Within Algorithmic Entry Frameworks
This article from Stock Traders Daily discusses Angiodynamics Inc. (NASDAQ: ANGO) within algorithmic entry frameworks, highlighting weak near-term sentiment despite potential long-term strength. It outlines various trading strategies including position trading, momentum breakout, and risk hedging strategies, each with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis indicating support and resistance levels for different horizons.
Freedom Broker initiates AngioDynamics stock coverage with buy rating
Freedom Broker has initiated coverage on AngioDynamics Inc. (NASDAQ: ANGO) with a buy rating and a price target of $16.00, suggesting a 59% upside despite the company's current unprofitability. The positive outlook is attributed to an improving growth profile as AngioDynamics shifts towards higher-growth medical technology platforms, including sustained momentum in Auryon and Mechanical Thrombectomy products, and anticipated commercialization of NanoKnife. This analysis follows AngioDynamics' recent fiscal Q3 2026 earnings, which surpassed revenue and EPS expectations, leading to updated guidance for fiscal 2026.
ANGO shares rise in pre-market after surpassing Q3 earnings estimates, though gross margin declines
AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of $0.07 for Q3 fiscal 2026, exceeding analyst estimates, and saw an 8.9% increase in revenue to $78.4 million. The growth was driven by strong sales in its Med Tech segment, particularly Auryon, mechanical thrombectomy products, and NanoKnife. Despite these positive results and an updated fiscal 2026 guidance with increased net sales projections, the company experienced a decline in pro forma gross margin and continues to report adjusted operating losses.
ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down
AngioDynamics, Inc. (ANGO) reported an adjusted loss per share narrower than expected for Q3 fiscal 2026, with revenues increasing 8.9% year-over-year to $78.4 million, beating analyst estimates. Despite strong growth in its Med Tech and Med Device businesses, the company's pro forma gross margin declined. AngioDynamics revised its fiscal 2026 guidance upward for net sales and Med Tech/Med Device revenue growth, while narrowing its projected adjusted loss per share.
Canaccord Genuity Group Has Lowered Expectations for AngioDynamics (NASDAQ:ANGO) Stock Price
Canaccord Genuity Group reduced its price target for AngioDynamics (NASDAQ:ANGO) from $18 to $16 but maintained a "buy" rating, indicating a potential upside of 62% from the current price. Analyst ratings for AngioDynamics are mixed, with a consensus "Hold" rating and an average target price of $18.67. The company's stock trades at $9.86, has a market cap of $406 million, and despite beating earnings and revenue estimates last quarter, remains unprofitable with a forecasted -$0.37 EPS for the year.
Freedom Broker initiates AngioDynamics stock coverage with buy rating
Freedom Broker has initiated coverage on AngioDynamics Inc. (NASDAQ: ANGO) with a buy rating and a $16.00 price target, representing a 59% upside, citing an improving growth profile and momentum in specific product lines. Despite the positive outlook, the company is not expected to be profitable this year. This latest analyst action follows AngioDynamics' strong fiscal Q3 2026 earnings report, where it surpassed EPS and revenue expectations, leading Canaccord to reaffirm its Buy rating while slightly adjusting its price target.
Freedom Broker initiates coverage of AngioDynamics (ANGO) with buy recommendation
Freedom Broker has initiated coverage of AngioDynamics (ANGO) with a "buy" recommendation. This move suggests a positive outlook from the brokerage firm regarding the company's future stock performance and business prospects, potentially attracting investor interest.
AngioDynamics Earnings Call Highlights Med Tech Momentum
AngioDynamics (ANGO) reported strong Q3 earnings with an 8.9% year-over-year revenue increase, driven by significant growth in its Med Tech segment. The company raised its full-year revenue and adjusted EBITDA guidance, signaling confidence in its strategic pivot towards higher-growth, higher-margin therapies like Auryon, AlphaVac, AngioVac, and NanoKnife. Despite facing headwinds from tariffs, manufacturing transitions, and higher operating costs impacting margins and cash flow, the management highlighted robust commercial momentum and accelerated adoption across its key Med Tech platforms.
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2026 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO) reported strong Q3 2026 earnings, leading them to raise full-year guidance for the third consecutive quarter. The company saw impressive growth in its Med Tech segment, particularly with Auryon and Mechanical Thrombectomy products, indicating their strategy to focus on high-margin markets is succeeding. Despite challenges like tariffs and inflation, AngioDynamics maintained profitability and expects continued growth, especially from AlphaVac, while also addressing leadership transition and the passing of a key R&D leader.
AngioDynamics (NASDAQ: ANGO) Q3 2026 revenue up 9% while net loss grows
AngioDynamics (NASDAQ: ANGO) reported an 8.9% increase in Q3 2026 revenue to $78.4 million, driven by strong growth in its Med Tech segment. Despite increased sales, the company's net loss widened to $8.1 million, impacted by restructuring costs and CEO transition expenses. For the nine months ended February 28, 2026, revenue rose 10.0% to $233.6 million, and the net loss improved to $25.3 million from $27.9 million in the previous year.
AngioDynamics Q3: Revenue $78.4M, Loss per Share $(0.19)
AngioDynamics reported third-quarter net sales of $78.4 million, an 8.9% increase year-over-year, alongside a net loss of $8.1 million, or $(0.19) per diluted share. The company's operating loss was $(12.951) million, with a gross margin of 52.9% of sales. Growth was primarily driven by the Med Tech segment and U.S. direct sales, with positive momentum in key product lines despite an expanded net loss.
AngioDynamics Inc (NASDAQ:ANGO) Beats Q3 Earnings Estimates and Raises Full-Year Guidance
AngioDynamics Inc (NASDAQ:ANGO) reported strong fiscal Q3 2026 results, surpassing analyst expectations for revenue and significantly beating on earnings per share. The company's Med Tech segment demonstrated robust growth, leading management to raise its full-year fiscal 2026 guidance for net sales, Med Tech growth, Adjusted EBITDA, and Adjusted EPS, despite a negative pre-market market reaction. This performance indicates a successful pivot towards high-growth technology platforms and strong underlying business momentum.
AngioDynamics, Inc. Q3 2026 Earnings Call Summary
AngioDynamics, Inc. reported strong Q3 2026 results driven by a strategic shift to high-margin Med Tech markets, with Auryon and Mechanical Thrombectomy portfolios showing double-digit growth. The company raised its full-year net sales and adjusted EBITDA guidance, anticipating continued expansion for products like NanoKnife internationally and the AlphaReturn Blood Management System. Despite facing headwinds from tariffs and manufacturing transition costs, AngioDynamics expects to generate substantial cash flow in Q4 and maintain its growth trajectory.
AngioDynamics (NASDAQ:ANGO) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS
AngioDynamics (NASDAQ:ANGO) reported strong Q3 earnings, beating analyst estimates by $0.13 EPS with revenue of $78.4 million, an 8.9% year-over-year increase. The company also raised its FY26 net sales guidance and adjusted EBITDA, driven by significant growth in its MedTech products like Auryon, AlphaVac, and NanoKnife. Despite these positive results, the company faces challenges with gross margin decline due to tariffs and manufacturing transitions, potentially leading to slightly negative FY26 cash flow.
AngioDynamics, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:ANGO) 2026-04-02
AngioDynamics, Inc. (NASDAQ: ANGO) has released its Q3 2026 earnings call presentation. This slide deck accompanies the company's financial results discussion for the third quarter of 2026. The presentation provides details related to their performance for the quarter.
AngioDynamics (ANGO) Posts Third Quarter Loss, Surpasses Revenue Expectations
AngioDynamics (ANGO) reported a smaller-than-expected quarterly loss of $0.07 per share, beating the Zacks Consensus Estimate of $0.11 per share. The company also surpassed revenue expectations, generating $78.42 million against an estimate of $72 million for the quarter ending February 2026. Despite a 7% decline in shares year-to-date, AngioDynamics has consistently outperformed EPS and revenue forecasts over the past four quarters.
[8-K] ANGIODYNAMICS INC Reports Material Event
AngioDynamics Inc. (NASDAQ: ANGO) reported its fiscal Q3 2026 results, showing net sales of $78.4 million, an 8.9% year-over-year increase, driven by strong growth in its Med Tech segment. Despite continued GAAP net losses, the company raised its full-year 2026 guidance for net sales, Med Tech growth, adjusted EBITDA, and adjusted EPS, reflecting confidence in its strategic execution. The report also highlights the company's debt-free balance sheet with $37.8 million in cash, though a planned increase in inventory due to vendor sterilization shutdowns may result in slightly negative full-year cash flow.
AngioDynamics: Fiscal Q3 Earnings Snapshot
AngioDynamics Inc. (ANGO) reported a loss of $8.1 million, or 19 cents per share, in its fiscal third quarter. Adjusted losses were 7 cents per share, with the medical device maker posting revenue of $78.4 million. The company expects full-year results to range from a loss of 30 cents to 23 cents per share, with revenue between $313.5 million and $315.5 million.
AngioDynamics beats estimates on Med Tech strength, stock up nearly 3%
AngioDynamics Inc. (NASDAQ:ANGO) reported strong fiscal Q3 2026 results, surpassing analyst expectations with an adjusted loss per share of -$0.07 and revenue of $78.4 million. The company's Med Tech segment saw significant growth, particularly in its mechanical thrombectomy portfolio, leading to a 2.85% rise in pre-market trading. AngioDynamics also raised its fiscal 2026 revenue guidance for the third consecutive quarter, reflecting continued strong performance.
AngioDynamics (NASDAQ:ANGO) Downgraded to Hold Rating by Zacks Research
AngioDynamics (NASDAQ:ANGO) has been downgraded from a "strong-buy" to a "hold" rating by Zacks Research, with other firms also trimming their ratings. The stock's consensus rating is now "Hold" with a target price of $19.33. Shares opened at $11.37, showing a market capitalization of $468.67 million and a negative P/E of -16.97.
AngioDynamics investors can watch Needham conference webcast April 14
AngioDynamics (NASDAQ: ANGO) announced that its management team will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 8:45 a.m. (ET). A live webcast of the presentation will be available for investors to access through the "Investors" section of the company's website. The presentation will also be available for replay after the event.
AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
AngioDynamics, Inc. announced that its management team will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 8:45 a.m. ET. A live webcast and replay of the presentation will be available on the company's website. AngioDynamics is a medical technology company focused on vascular systems and cancer treatment.
Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Decreases By 18.0%
AngioDynamics (NASDAQ:ANGO) experienced an 18.0% decrease in short interest in March, totaling 1,784,550 shares as of March 13th. This represents about 4.6% of the company's shares shorted and a days-to-cover ratio of 6.3 days. Shares opened at $10.90, and institutional investors own 89.43% of the stock, while analysts rate it a "Moderate Buy" with a $19.33 price target.
